Does interferon precipitate rejection of liver allografts?
1995; Lippincott Williams & Wilkins; Volume: 22; Issue: 4 Linguagem: Inglês
10.1002/hep.1840220446
ISSN1527-3350
AutoresAlbert D. Min, Henry C. Bodenheimer,
Tópico(s)Transplantation: Methods and Outcomes
ResumoHepatologyVolume 22, Issue 4 p. 1333-1335 EditorialFree Access Does interferon precipitate rejection of liver allografts? Albert D. Min MD, Albert D. Min MD Division of Hepatology Mount Sinai School of Medicine New York, NYSearch for more papers by this authorHenry C. Bodenheimer Jr MD, Corresponding Author Henry C. Bodenheimer Jr MD Division of Hepatology Mount Sinai School of Medicine New York, NYDivision of Hepatology, Box 1039, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574===Search for more papers by this author Albert D. Min MD, Albert D. Min MD Division of Hepatology Mount Sinai School of Medicine New York, NYSearch for more papers by this authorHenry C. Bodenheimer Jr MD, Corresponding Author Henry C. Bodenheimer Jr MD Division of Hepatology Mount Sinai School of Medicine New York, NYDivision of Hepatology, Box 1039, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574===Search for more papers by this author First published: October 1995 https://doi.org/10.1002/hep.1840220446Citations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Wright TL, Donegan E, Hsu H, Ferrell L, Lake JR, Kim M, Combs C, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317–322. 10.1016/0016-5085(92)91129-R CASPubMedWeb of Science®Google Scholar 2 Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, Ascher NL, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994–999. 10.1016/0016-5085(94)90759-5 CASPubMedWeb of Science®Google Scholar 3 Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30–34. 10.1002/hep.1840210107 CASPubMedWeb of Science®Google Scholar 4 Schluger LK, Min A, Wolf DC, Sheiner P, Cubukcu O, Thung SN, Bodenheimer H. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation [Abstract]. Gastroenterology 1994; 106: A978. Web of Science®Google Scholar 5 Wright HI, Gavaler JS, Van Thiel DH. Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allografts recipients. Transplantation 1992; 53: 121–124. 10.1097/00007890-199201000-00023 PubMedWeb of Science®Google Scholar 6 Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773–779. 10.1002/hep.1840200402 CASPubMedWeb of Science®Google Scholar 7 Rezieg M, Altraif I, Roach C, Greig P, Cole E, Krajden M, Levy G. Treatment of hepatitis C viral infection (HCV) in transplanted patients with ribavarin [Abstract]. Hepatology 1993; 18: 342A. 10.1016/0270-9139(93)92893-5 Web of Science®Google Scholar 8 Féray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, Reynès M, et al. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22: 1084–1089. 10.1002/hep.1840220411 CASPubMedWeb of Science®Google Scholar 9 Peters M. Mechanisms of action of interferon. Semin Liver Dis 1989; 9: 235–239. 10.1055/s-2008-1040516 PubMedWeb of Science®Google Scholar 10 Benizri EJ, Gugenheim J, Bernard G, Tovey MG. Role of interferon alpha in allograft rejection. Transplant Proc 1995; 27: 413. CASPubMedWeb of Science®Google Scholar 11 Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, Smolen J-Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 1988; 45: 402–405. 10.1097/00007890-198802000-00031 PubMedWeb of Science®Google Scholar 12 Kramer P, Ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte in interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989–990. 10.1016/S0140-6736(84)92327-4 CASPubMedWeb of Science®Google Scholar 13 Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, Gilbert J, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation: effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 1979; 300: 1345–1349. 10.1056/NEJM197906143002401 CASPubMedWeb of Science®Google Scholar 14 Lui SF, Ali AA, Grundy JE, Fernando ON, Griffiths PD, Sweny P. Double-blind, placebo-controlled trial of human lymphoblas-toid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1992; 7: 1230–1237. PubMedWeb of Science®Google Scholar 15 Hanafusa T, Ichikawa Y, Kyo M, Fukunishi T, Nagano S, Nakayama K, Nishiuchi M, et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. Transplant Proc 1995; 27: 956–957. CASPubMedWeb of Science®Google Scholar 16 Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects. Transplant Proc 1995; 27: 948–950. PubMedWeb of Science®Google Scholar 17 Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alphainterferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995; 27: 1222–1223. PubMedWeb of Science®Google Scholar 18 Davies HFFS, Pollard SG, Calne RY. Soluble HLA antigens in the circulation of liver graft recipients. Transplantation 1989; 47: 524–527. 10.1097/00007890-198903000-00025 CASPubMedWeb of Science®Google Scholar 19 Hopf U, Neuhaus P, Lobeck H, König V, Köther S, Bauditz J, Bechstein W-O, et al. Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha. J Hepatol 1991; 13: 339–346. 10.1016/0168-8278(91)90078-P PubMedWeb of Science®Google Scholar 20 Sheiner PA, Fisher A, Schluger LK, Bodenheimer H, Mor E, Emre S, Schwartz ME, et al. Treatment with alpha-interferon does not alter the course of recurrence of hepatitis C [Abstract]. Hepatology 1994; 20: 133A. Google Scholar 21 Loinaz C, Lumbreras C, Colina F, Gomez R, Fuertes A, Alvarado A, Garcia I, et al. High incidence of post-transplant hepatitis and chronic rejection associated with HCV infection in liver transplant recipients. [Abstract]. Proceeding of XVth World Congress of the Transplantation Society 1994; A285. Google Scholar 22 Bronsther O, Manez R, Kusne S. Irish W, Roland W, Jain A, Llull R, et al. Recurrent or de novo B and C hepatitis influence the development of vanishing bile duct syndrome after liver transplantation. [Abstract]. Proceeding of XVth World Congress of the Transplantation Society 1994; A161. Google Scholar Citing Literature Volume22, Issue4October 1995Pages 1333-1335 ReferencesRelatedInformation
Referência(s)